retatrutide triple agonist glp-1 gip glucagon receptor Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide triple agonist glp-1 gip

For example, uncomfortable fullness has the potential to be reported as nausea by one participant, but not another

Slow dose escalation mitigates these effects substantially, and discontinuation due to gastrointestinal intolerance ranges from 3% to 16% across agents, being highest for GLP-1/glucagon dual agonists (e.g., survodutide)

Epub 2023 Oct 10

doi: 10.1016/j.jhepr.2019.07.002 92 MllerTDFinanBBloomSRDAlessioDDruckerDJFlattPRet al

GLP-1 Receptor Agonist Market Dynamics Market Drivers Growth in Obesity Treatment Reimbursement and Rapid Expansion of Large-scale Peptide Manufacturing Drives Market The expansion of reimbursement coverage for anti-obesity medications and the inclusion of GLP-1 receptor agonists in clinical treatment guidelines are significantly increasing patient access and prescription volumes

Additionally, recommendations for fiber and magnesium supplements are included to help manage GI side effects protein shakes to preserve muscle mass